Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.
Hussein AkilMercedes QuintanaJeremy H RaymondTommy BillouxValentin BenboubkerSophie BessePhilippe AuzelouxVéronique DelmasValérie PetitLionel LarueMichel D'IncanFrançoise DegoulJacques RouanetPublished in: Cancers (2021)
Our data suggest that [131I]ICF01012-TRT and MEKi combination could be of benefit for advanced pigmented BRAF-mutant melanoma care and that [131I]ICF01012 alone could constitute a new potential NRAS-mutant melanoma treatment.